Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 622 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How Fatty Liver Disease Helps Cancer Thrive in the Liver July 6, 2023 Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for... February 4, 2025 Long-Term Responders with No Evidence of Disease Have Better Survival to... May 16, 2022 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Load more HOT NEWS Skin cancer death rates in men risen dramatically in the last... EMA Recommends Extension of Indications for Ribociclib to Include Use in... Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... High School Holds Early Graduation Ceremony For Teen With Terminal Cancer
